Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ESPR

ESPR - Esperion Therapeutics Inc Stock Price, Fair Value and News

$2.44-0.03 (-1.21%)
Market Closed

38/100

ESPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

ESPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ESPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ESPR Price Action

Last 7 days

-10.3%

Last 30 days

-29.5%

Last 90 days

-36.6%

Trailing 12 Months

62.7%

ESPR RSI Chart

ESPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ESPR Valuation

Market Cap

626.6M

Price/Earnings (Trailing)

-27.63

Price/Sales (Trailing)

1.55

Price/Free Cashflow

-47.86

ESPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

403.1M

Rev. Growth (Yr)

143.73%

Rev. Growth (Qtr)

92.93%

ESPR Earnings

Earnings (TTM)

-22.7M

Earnings Growth (Yr)

390.04%

Earnings Growth (Qtr)

297.34%

ESPR Profitability

Return on Equity

7.51%

Return on Assets

-4.87%

Free Cashflow Yield

-2.09%

ESPR Investor Care

Shares Dilution (1Y)

29.80%

Diluted EPS (TTM)

-0.11

ESPR Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025259.6M268.1M303.8M403.1M
2024229.7M277.8M295.5M332.3M
202381.0M87.9M102.9M116.3M
202289.3M67.5M72.1M75.5M
2021233.7M62.1M72.7M78.4M
2020168.2M188.0M207.8M227.5M
2019000148.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Esperion Therapeutics Inc

ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
 CEO
 WEBSITEesperion.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES199

Esperion Therapeutics Inc Frequently Asked Questions

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Esperion Therapeutics Inc is 626.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ESPR's PE ratio (Price to Earnings) is -27.63 and Price to Sales (PS) ratio is 1.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Esperion Therapeutics Inc has provided -0.168 (multiply by 100 for percentage) rate of return.